Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Emergent BioSolutions | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Emergent BioSolutions

Contract manufacturing revenue up 29% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Emergent BioSolutions
3Q Revenues: $149.4 million (+5%)
3Q Earnings: $33.6 million (+65%)
YTD Revenues: $367.1 million (+9%)
YTD Earnings: $48.7 million (+61%)
Comments: Growth in the quarter was primarily driven by increased product sales, namely Other product sales, and contract manufacturing revenues, offset by lower contracts and grants revenue. Product sales were $114.3 million, up 18% attributable to other product sales and, specifically, sales related to the timing of BAT deliveries to the SNS and RSDL shipments to the DoD, along with international sales of VIGIV and Trobigard, all offset by lower BioThrax sales due to the timing of BioThrax deliveries to the SNS. Contract manufacturing revenue was $18.9 million in the quarter, up 29%, with an increase in fill/finish and bulk manufacturing services.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters